Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10708312			
Filing Date		2004-02-24			
First Named Inventor Todd		L DePue			
Art Unit		1732			
Examiner Name Lawre		ence Emile Lambelet			
Attorney Docket Number		MASLIAC-29			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Patentee or Applicant		Releva	Columns,Lines whe nt Passages or Rele Appear	
	1	6440514	B1	2002-08	-27	Ueno et al.				
	2	5839752		1999-11-24 Yamasaki et al.						
	3	5779262 1998-07-14 Totani et al.								
	4	5698283		1997-12	-16	Yamasaki et ai	L			
If you wis	h to a	dd additional U.S. Pater							Add	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	raminer Cite No Publication Number Kind Code1 Date			Name of Patentee of Applicant		Releva	Columns,Lines whe nt Passages or Rele s Appear			
	1									
If you wish to add additional U.S. Published Application citation information please click the Add button. Add									_	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*				Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or v	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	TS	

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708312		
iling Date		2004-02-24		
irst Named Inventor Todd		L. DePue		
Art Unit		1732		
xaminer Name Lawre		ence Emile Lambelet		
Attorney Docket Number		MASLIAC-29		

	1											
If you wish to add additional Foreign Patent Document citation information please click the Add button Add												
NON-PATENT LITERATURE DOCUMENTS Remove												
Examiner Initials*	Cite No	(book	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sprosium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishers.							Τs		
	1	U.S. Patent and Trademark Office Examiner ROBERT A. COKER, Office Action in Application Serial No. 10/904,032; dated July 16, 2007										
If you wish to add additional non-patent literature document citation information please click the Add button Add												
EXAMINER SIGNATURE												
Examiner	Signa	ture							Date Considered			
*EVAMINED: Initial if reference considered subother or not citation is in conformance with MDED COD. Draw line through a												

See Knd. Odde of USPTO Planto Documents at your, USPTO, DOV or MPEP 001.04. * Enter office an all assed for a document, by the to-electr code (WIPO Standard ST3.). **To Apparese parted convenents, the adulation of the year of the reign or the Engineer must proceed the serial number of the parted toodsman, "A find of comment by the appropriate symbol as a indicated on the document under WIPO Standard ST, 16 if possible. **Applicant is to place a check mark here (Engine) language arranation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708312		
Filing Date		2004-02-24		
First Named Inventor	Todd	L. DePue		
Art Unit		1732		
Examiner Name	Lawre	ence Emile Lambelet		
Attorney Docket Number		MASLIAC-29		

CERTIFICATION STATEMENT

Diagra can	37	CFR 1	97	and	1 98 to	make the	annonnista	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to let not information contained in the information disclosure statement was known to 3 any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3(f)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

_ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David W. Dorton/	Date (YYYY-MM-DD)	2007-08-09
Name/Print	David W. Dorton	Registration Number	51625

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.